Literature DB >> 23525101

The syndecan-4/protein kinase Cα pathway mediates prostaglandin E2-induced extracellular regulated kinase (ERK) activation in endothelial cells and angiogenesis in vivo.

Federico Corti1, Federica Finetti, Marina Ziche, Michael Simons.   

Abstract

Prostaglandin E2 (PGE2) is regarded as the main mediator of inflammatory symptoms. In addition, it also plays an important role in tumor growth and angiogenesis. In this study, we examined the mechanism of PGE2-induced angiogenic response. We show that in the absence of proteoglycan syndecan-4 (Sdc4), PGE2-induced ERK activation is decreased significantly, as is endothelial cell migration and cord formation in a two-dimensional Matrigel assay. In vivo, PGE2-induced angiogenesis is reduced dramatically in Sdc4(-/-) mice. The mechanism was traced to Sdc4-dependent activation of protein kinase Cα (PKCα). Transduction of an Sdc4 S183E mutant (a cytoplasmic domain mutation that blocks Sdc4-dependent PKCα activation) into Sdc4(-/-) endothelial cells was not able to rescue the loss of PGE2-induced ERK activation, whereas a transduction with full-length Sdc4 resulted in full rescue. Furthermore, PGE2-induced angiogenesis was also reduced in PKCα(-/-) mice. Taken together, these results demonstrate that PGE2-induced activation of angiogenesis is mediated via syndecan-4-dependent activation of PKCα.

Entities:  

Keywords:  Angiogenesis; Cell Signaling; Prostaglandins; Protein Kinase C (PKC); Proteoglycan; Syndecan 4

Mesh:

Substances:

Year:  2013        PMID: 23525101      PMCID: PMC3642317          DOI: 10.1074/jbc.M113.452383

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction.

Authors:  Yutaka Matsui; Masahiro Ikesue; Keiko Danzaki; Junko Morimoto; Mami Sato; Shinya Tanaka; Tetsuhito Kojima; Hiroyuki Tsutsui; Toshimitsu Uede
Journal:  Circ Res       Date:  2011-04-14       Impact factor: 17.367

2.  Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells.

Authors:  Chohreh Partovian; Rong Ju; Zhen W Zhuang; Kathleen A Martin; Michael Simons
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

3.  PGE2 promotes angiogenesis through EP4 and PKA Cγ pathway.

Authors:  Yushan Zhang; Yehia Daaka
Journal:  Blood       Date:  2011-09-16       Impact factor: 22.113

4.  Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia.

Authors:  Xibin Liang; Lu Lin; Nathaniel S Woodling; Qian Wang; Christoph Anacker; Tingting Pan; Milton Merchant; Katrin Andreasson
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

Review 5.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

6.  Prostaglandin E(2) primes the angiogenic switch via a synergic interaction with the fibroblast growth factor-2 pathway.

Authors:  Federica Finetti; Sandra Donnini; Antonio Giachetti; Lucia Morbidelli; Marina Ziche
Journal:  Circ Res       Date:  2009-08-27       Impact factor: 17.367

Review 7.  Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.

Authors:  R E Harris
Journal:  Inflammopharmacology       Date:  2009-04       Impact factor: 4.473

Review 8.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

Authors:  Peter M Rothwell; Jacqueline F Price; F Gerald R Fowkes; Alberto Zanchetti; Maria Carla Roncaglioni; Gianni Tognoni; Robert Lee; Jill F F Belch; Michelle Wilson; Ziyah Mehta; Tom W Meade
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

9.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.

Authors:  Peter M Rothwell; Michelle Wilson; Jacqueline F Price; Jill F F Belch; Tom W Meade; Ziyah Mehta
Journal:  Lancet       Date:  2012-03-21       Impact factor: 79.321

10.  Suppression of RhoG activity is mediated by a syndecan 4-synectin-RhoGDI1 complex and is reversed by PKCalpha in a Rac1 activation pathway.

Authors:  Arye Elfenbein; John M Rhodes; Julia Meller; Martin A Schwartz; Michiyuki Matsuda; Michael Simons
Journal:  J Cell Biol       Date:  2009-07-06       Impact factor: 10.539

View more
  17 in total

1.  Syndecan 4 is required for endothelial alignment in flow and atheroprotective signaling.

Authors:  Nicolas Baeyens; Mary Jo Mulligan-Kehoe; Federico Corti; David D Simon; Tyler D Ross; John M Rhodes; Thomas Z Wang; Cecile O Mejean; Michael Simons; Jay Humphrey; Martin A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

2.  Syndecan-2 selectively regulates VEGF-induced vascular permeability.

Authors:  F Corti; E Ristori; F Rivera-Molina; D Toomre; J Zhang; J Mihailovic; Z W Zhuang; M Simons
Journal:  Nat Cardiovasc Res       Date:  2022-05-16

3.  SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk.

Authors:  Sofia I Vuorinen; Rachel K Okolicsanyi; Martina Gyimesi; Jacob Meyjes-Brown; Deepa Saini; Son H Pham; Lyn R Griffiths; Larisa M Haupt
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-24       Impact factor: 4.322

4.  VE-statin/Egfl7 expression in malignant glioma and its relevant molecular network.

Authors:  Chunhai Huang; Xianrui Yuan; Yi Wan; Fei Liu; Xiaoyu Chen; Xianquan Zhan; Xuejun Li
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

5.  Pathological Angiogenesis Requires Syndecan-4 for Efficient VEGFA-Induced VE-Cadherin Internalization.

Authors:  Giulia De Rossi; Maria Vähätupa; Enrico Cristante; Samantha Arokiasamy; Sidath E Liyanage; Ulrike May; Laura Pellinen; Hannele Uusitalo-Järvinen; James W Bainbridge; Tero A H Järvinen; James R Whiteford
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-02-18       Impact factor: 10.514

6.  RANTES/CCL5 mediated-biological effects depend on the syndecan-4/PKCα signaling pathway.

Authors:  Loïc Maillard; Naoaki Saito; Hanna Hlawaty; Véronique Friand; Nadine Suffee; Fanny Chmilewsky; Oualid Haddad; Christelle Laguillier; Erwan Guyot; Takehiko Ueyama; Olivier Oudar; Angela Sutton; Nathalie Charnaux
Journal:  Biol Open       Date:  2014-09-26       Impact factor: 2.422

7.  Inhibition of protein kinase C enhances angiogenesis induced by platelet-derived growth factor C in hyperglycemic endothelial cells.

Authors:  Junji Moriya; Napoleone Ferrara
Journal:  Cardiovasc Diabetol       Date:  2015-02-07       Impact factor: 9.951

8.  Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis.

Authors:  Oualid Haddad; Erwan Guyot; Nicolas Marinval; Fabien Chevalier; Loïc Maillard; Latifa Gadi; Christelle Laguillier-Morizot; Olivier Oudar; Angela Sutton; Nathalie Charnaux; Hanna Hlawaty
Journal:  Mar Drugs       Date:  2015-10-28       Impact factor: 5.118

9.  Syndecan-4 negatively regulates antiviral signalling by mediating RIG-I deubiquitination via CYLD.

Authors:  Wei Lin; Jing Zhang; Haiyan Lin; Zexing Li; Xiaofeng Sun; Di Xin; Meng Yang; Liwei Sun; Lin Li; Hongmei Wang; Dahua Chen; Qinmiao Sun
Journal:  Nat Commun       Date:  2016-06-09       Impact factor: 14.919

10.  Killing two birds with one stone: dual blockade of integrin and FGF signaling through targeting syndecan-4 in postoperative capsular opacification.

Authors:  Yingyan Qin; Yi Zhu; Furong Luo; Chuan Chen; Xiaoyun Chen; Mingxing Wu
Journal:  Cell Death Dis       Date:  2017-07-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.